肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2010年
3期
158-160
,共3页
乳腺增生%乳腺肿瘤%受体,雌激素%受体,孕激素
乳腺增生%乳腺腫瘤%受體,雌激素%受體,孕激素
유선증생%유선종류%수체,자격소%수체,잉격소
Hyperplasia of mammary glands%Breast neoplasms%Receptors,estrogen%Receptors,progestin
目的 探讨乳腺增生及乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)的表达差异及其临床意义.方法 采用免疫组织化学方法检测68例乳腺增生和168例乳腺癌标本中ER、PR的表达.结果 乳腺癌患者ER表达水平明显高于乳腺增生患者(P＜0.05),而PR在两组中的表达差异无统计学意义.绝经后乳腺癌患者ER表达水平中位值为30%,明显高于绝经后乳腺增生患者的10%(P＜0.05),而在绝经前两组患者ER表达水平差异无统计学意义.浸润性小叶癌组织内PR的表达明显高于浸润性导管癌等其他类型,差异有统计学意义(P=0.005).结论 ER、PR的表达能够较好地反映乳腺疾病的病理生物学特征.
目的 探討乳腺增生及乳腺癌組織中雌激素受體(ER)、孕激素受體(PR)的錶達差異及其臨床意義.方法 採用免疫組織化學方法檢測68例乳腺增生和168例乳腺癌標本中ER、PR的錶達.結果 乳腺癌患者ER錶達水平明顯高于乳腺增生患者(P＜0.05),而PR在兩組中的錶達差異無統計學意義.絕經後乳腺癌患者ER錶達水平中位值為30%,明顯高于絕經後乳腺增生患者的10%(P＜0.05),而在絕經前兩組患者ER錶達水平差異無統計學意義.浸潤性小葉癌組織內PR的錶達明顯高于浸潤性導管癌等其他類型,差異有統計學意義(P=0.005).結論 ER、PR的錶達能夠較好地反映乳腺疾病的病理生物學特徵.
목적 탐토유선증생급유선암조직중자격소수체(ER)、잉격소수체(PR)적표체차이급기림상의의.방법 채용면역조직화학방법검측68례유선증생화168례유선암표본중ER、PR적표체.결과 유선암환자ER표체수평명현고우유선증생환자(P＜0.05),이PR재량조중적표체차이무통계학의의.절경후유선암환자ER표체수평중위치위30%,명현고우절경후유선증생환자적10%(P＜0.05),이재절경전량조환자ER표체수평차이무통계학의의.침윤성소협암조직내PR적표체명현고우침윤성도관암등기타류형,차이유통계학의의(P=0.005).결론 ER、PR적표체능구교호지반영유선질병적병리생물학특정.
Objective To investigate the expression of ER and PR in hyperplasia of mammary glands and breast cancer. Methods The expression of ER and PR in 68 hyperplasia of mammary glands cases and 168 breast cancer cases were quantified by immunohistochemical method. Results The expression of ER in breast cancer(30%) was significantly higher than that in hyperplasia of mammary glands(10 %)(P ＜0.05) and there was no significant difference in PR between them. The expression of ER in postmenopausal breast cancer was significantly higher than that in postmenopausal hyperplasia of mammary glands (P ＜0.05) and there was no significant difference in ER between two premenopausal groups. The expression of PR in invasive lobular carcinoma was significantly higher than that in invasive ductal carcinoma and other types (P=0.005).Conclusion The expression of ER and PR may identify the characteristics of patholobiology in breast disease.
